Nordic Pharma, Inc., a subsidiary of Nordic Group BV, introduced LACRIFILL Canalicular Gel, an innovative therapy for dry eye, in the U.S. this April and is showcasing it to leading ophthalmologists at AAO 2024. This cross-linked hyaluronic acid gel, approved by the FDA, temporarily blocks tear drainage by occluding the canalicular system, allowing patients’ eyes to remain bathed in their natural tears.
LACRIFILL is customized for each patient and is administered via a straightforward in-office procedure, reimbursed under CPT code 68761. The effects last for up to six months.
Phil Gioia, U.S. Team Chair, expressed excitement about representing Nordic Pharma at the AAO, highlighting the event’s significance alongside the attendance of the U.S. Medical Advisory Board and a recent study published in the Journal of Cataract and Refractive Surgery (JCRS). “This is the perfect opportunity to showcase how LACRIFILL is transforming dry eye treatment,” he stated.
The October JCRS issue features an article on the effectiveness and safety of LACRIFILL by notable ophthalmologists, confirming that the cross-linked hyaluronic acid is a safe and effective option for dry eye management. The clinical trial demonstrated significant improvements in symptoms and key metrics such as Schirmer score and corneal staining, with effects lasting six months.
Dr. Neel R. Desai from the Eye Institute of West Florida noted the ease and comfort of administering LACRIFILL, leading him to incorporate it into his standard protocols for managing dry eye prior to refractive cataract surgery.
Attendees at AAO are invited to visit booth 4062 on Saturday, October 19, at 2:00 p.m. for a discussion on “Dry Eye Disease: LACRIFILL® and Reimbursement,” followed by a Q&A session. Orders can also be placed at the booth.
Nordic Pharma is proud to sponsor the Women In Ophthalmology (WIO) Awards Ceremony & Networking Reception at AAO. Dr. Lisa M. Nijm emphasized the company’s commitment to supporting exceptional women in ophthalmology and improving patient care.
For more information on LACRIFILL Canalicular Gel and ordering, visit lacrifill.com.
About Nordic Group BV
Nordic Group BV is a mid-sized, privately held international pharmaceutical company focused on developing and marketing specialty products, particularly in eye care, rheumatology, and women’s health. The company has a strong presence in Europe and is expanding globally through targeted acquisitions.
About Nordic Pharma, Inc.
Nordic Pharma, Inc. leverages expertise from established global biopharmaceutical companies, specializing in bringing biotechnology-derived drugs to market and utilizing advanced sterile manufacturing technologies.
